{"id":"W2751303173","doi":"10.1111/imj.67_13578","title":"P67: LONG‐TERM MANAGEMENT OF MODERATE‐TO‐SEVERE ATOPIC DERMATITIS WITH DUPILUMAB AND CONCOMITANT TOPICAL CORTICOSTEROIDS: A 1‐YEAR RANDOMIZED, PLACEBO‐CONTROLLED PHASE 3 TRIAL (CHRONOS)","year":2017,"lang":"en","type":"article","venue":"Internal Medicine Journal","topic":"Dermatology and Skin Diseases","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"ca_institutions":"SKiN Health","funders":"","keywords":"Medicine; Eczema Area and Severity Index; Atopic dermatitis; Dupilumab; Placebo; Concomitant; Regimen; Internal medicine; Randomized controlled trial; Placebo-controlled study; Clinical endpoint; Adverse effect; Dermatology; Double blind; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005015222,0.0002717868,0.001687369,0.0001713968,0.0002180612,0.00008515321,0.0002788492,0.00009123291,0.000712803],"category_scores_gemma":[0.0005148925,0.000161536,0.0002028341,0.00002996891,0.0006330727,0.0001762223,0.0001032478,0.0004143481,0.000009497179],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0000618854,"about_ca_system_score_gemma":0.00008958845,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00001983798,"about_ca_topic_score_gemma":0.00001108516,"domain_scores_codex":[0.9977309,0.0002025899,0.001008982,0.000248213,0.000503574,0.0003057775],"domain_scores_gemma":[0.9979485,0.0002710295,0.0006696959,0.0003974005,0.0001915427,0.0005217773],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.957271,0.000407116,0.02516246,0.0002511015,0.002059316,0.004335759,0.000435695,0.00000152715,0.00003489593,0.0001658066,0.004083926,0.005791428],"study_design_scores_gemma":[0.9393572,0.002393773,0.04436783,0.003551693,0.001609164,0.007582888,0.0002081665,0.0002790952,0.00007730327,0.0002939972,0.0001178634,0.0001610456],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9811772,0.001137023,0.005394537,0.004605194,0.0007689681,0.001750505,0.000005318357,0.00001602591,0.005145253],"genre_scores_gemma":[0.9964142,0.0004589675,0.000371394,0.0006192293,0.0005702946,0.00007173558,0.000003140613,0.00001953227,0.001471498],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01920537,"threshold_uncertainty_score":0.7804694,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01660365024919002,"score_gpt":0.3193064312026972,"score_spread":0.3027027809535072,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}